Carbaglu

USDailyMed:Carglumic acid AU:B1 A16AA05(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-only (2S)-2-(carbamoylamino)pentanedioic acid 1188-38-1N 121396 7458 DB06775Y 1265942N108351N 5L0HB4V1EW D07130Y CHEBI:71028N ChEMBL1201780N DTXSID7046706 Interactive image C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1YKey:LCQLHJZYVOQKHU-VKHMYHEASA-NY Carglumic acid, sold under the brand nameCarbagluamong others, is used for the treatment ofhyperammonaemia.Carglumic acid is acarbamoyl phosphate synthetase 1(CPS 1) activator. The most common adverse effects include vomiting, abdominal pain,pyrexia(fever), andtonsillitis,anemia, diarrhea, ear infection, other infections,nasopharyngitis, decreasedhemoglobinlevels, and headache. It was approved for medical use in the United States in March 2010.Carglumic acid is anorphan drug.It is available as ageneric medication.